Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer
about
A nation-wide multicenter 10-year (1999-2008) retrospective clinical study of endocrine therapy for Chinese females with breast cancer.The influence of CGS 16949A on peripheral aromatisation in breast cancer patients.Endocrine and clinical consequences of combination tamoxifen-aminoglutethimide in postmenopausal breast cancer.Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer.Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients.Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.Role of aminoglutethimide in male breast cancerSuppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer.The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients.High dose ketoconazole: endocrine and therapeutic effects in postmenopausal breast cancer.Treatment of breast cancer with aromatase inhibitors--current status and future prospectsNew endocrine drugs for treatment of advanced breast cancer.Endocrine therapy of metastatic breast cancer.Hormone receptor assays: clinical usefulness in the management of carcinoma of the breast.Could aminoglutethimide replace adrenalectomy?DHEA: a biologist's perspective.Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer.Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone.
P2860
Q33921197-3E401889-511C-4818-BF93-F7D76287ED41Q35984346-1CCF65C3-8BEA-4F60-AE28-C7F9CC5B7A81Q35991573-B47C57F5-072B-407B-8481-4077C2CB796EQ35992084-6BDB1079-10FB-499B-AC6C-334C84B2262EQ35992412-8187A0C5-4311-40F6-AFE5-F2F60D9D25EDQ35992446-DF2B8E59-D048-4A28-B8A2-658C8E6AB652Q35992680-629516C4-3255-4D43-98E9-95835B1EC914Q35993244-88BFFA45-CBE8-4A98-82E1-BE0855405E2DQ36027398-CC76BE38-4F00-476C-B1E7-675B748B9C43Q36048194-ADA45D5F-2998-4844-A697-4A9A9A725BB5Q36465836-6F77BE49-5574-47DA-90E4-6DD54762003EQ36466704-DB3B05BD-0444-4D51-A53D-02F32EFDABBDQ36468107-60874B13-63D3-4A92-B159-DECE7C1F7EDAQ37938324-45DED4B2-5B45-4A18-A2AB-7FB592D8451FQ38363146-F2C40ED6-4EFD-4F5A-8518-1D8BE79E4619Q39318408-DBBB8EF4-BA4D-4818-9EF5-17DC1285CD0BQ39840475-3C89632F-9361-4E9C-9005-1FC8189C1064Q41636648-EFA2909F-8B11-4DE7-936F-995B5DE0DDBBQ42478905-E88B3F04-5119-459F-BAC9-643AD4D6B21DQ46758388-0D2A8A37-894B-40E0-BE4E-C6D3E19A6ECCQ54002508-45524E59-5F2E-411F-8A12-48918EA236D2
P2860
Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer
description
1983 nî lūn-bûn
@nan
1983年の論文
@ja
1983年論文
@yue
1983年論文
@zh-hant
1983年論文
@zh-hk
1983年論文
@zh-mo
1983年論文
@zh-tw
1983年论文
@wuu
1983年论文
@zh
1983年论文
@zh-cn
name
Endocrine effects of low dose ...... d postmenopausal breast cancer
@ast
Endocrine effects of low dose ...... d postmenopausal breast cancer
@en
type
label
Endocrine effects of low dose ...... d postmenopausal breast cancer
@ast
Endocrine effects of low dose ...... d postmenopausal breast cancer
@en
prefLabel
Endocrine effects of low dose ...... d postmenopausal breast cancer
@ast
Endocrine effects of low dose ...... d postmenopausal breast cancer
@en
P2093
P2860
P356
P1476
Endocrine effects of low dose ...... d postmenopausal breast cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/BJC.1983.100
P407
P577
1983-05-01T00:00:00Z